Editorial commentary on the clinical trial demonstrating that GHRH/tesamorelin administration improves cognitive function in healthy older adults and patients with mild cognitive impairment, contextualizing these findings within the growing evidence for GH-axis involvement in brain aging and cognitive decline. Provides neuroendocrinology perspective on tesamorelin cognition data. Highlights the significance of the GHRH cognitive improvement data for the neuroendocrinology field—identifying GH-axis stimulation as a potentially actionable mechanism for cognitive preservation in aging and MCI, and situating tesamorelin as a candidate neuroprotective intervention with a known safety profile.
McLarnon, Andy